Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model

Arash Pourgholaminejad, Arezoo Jamali, Morteza Samadi-Foroushani, Afshin Amari, Reza Mirzaei, Bita Ansaripour, Nemat Khansari, Mohammad Reza Aghasadeghi, Babak Baban, Jamshid Hadjati

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

CpG motifs have been advanced as agents that stimulate the maturation of DCs for immunotherapy. The present study tested the hypothesis that multiple doses of CpG-matured DC vaccine would be efficacious for complete eradication of experimentally-induced tumor. Accordingly, WEHI164 cells were implanted subcutaneously in the flank of BALB/c mice. During DC culture, tumor lysate was added to immature DCs followed by addition of CpG or non-CpG control 4-6 h later. A total of three doses of CpG or non-CpG control-matured DCs were injected around tumors. The results showed that multiple doses of CpG-matured DCs led to considerable decrease in cytotoxicity of lymphocytes and significantly increased tumor growth rate compared to a single dose. Further, mice which received three doses of the vaccine also displayed significant FoxP3 in tumor tissue. In conclusion, multiple doses of CpG-matured DCs exhibited decreased anti-tumor immunity in association with increased expression of FoxP3.

Original languageEnglish (US)
Pages (from-to)360-364
Number of pages5
JournalCellular Immunology
Volume271
Issue number2
DOIs
StatePublished - 2011

Keywords

  • Cell therapy
  • FoxP3
  • Synthetic oligodeoxynucleotides
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Immunology

Fingerprint

Dive into the research topics of 'Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model'. Together they form a unique fingerprint.

Cite this